Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Inhaled nitric oxide in adults with pulmonary hypertension

Darren B Taichman, MD, PhD
Section Editor
Jess Mandel, MD
Deputy Editor
Geraldine Finlay, MD


The inhalation of nitric oxide (NO) has been proposed as long-term therapy for pulmonary arterial hypertension (PAH), and possibly other types of pulmonary hypertension (PH), because NO-mediated signaling is decreased in patients with PAH. Such a role, however, has not been established due in part to practical limitations associated with its administration, an area of continued study [1]. Currently, the only widely accepted role for inhaled NO is as a vasodilator during a vasoreactivity trial. Its use has also been reported in acutely ill patients with severe PH.

In this topic review, the role of NO in the pathogenesis of PAH is described. Diagnostic and therapeutic uses of inhaled NO in adults with PH are then discussed.

The definition, classification, epidemiology, etiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of PH are discussed elsewhere. The use of inhaled NO in the management of patients with acute respiratory distress syndrome (ARDS) and in the management of infants with persistent PH are also discussed separately. (See "Overview of pulmonary hypertension in adults" and "Acute respiratory distress syndrome: Novel therapies in adults" and "Persistent pulmonary hypertension of the newborn".)


The World Health Organization (WHO) classifies patients with pulmonary hypertension (PH) into five groups based upon etiology. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have PH (table 1). When all five groups are discussed collectively, PH is generally used. We adhere to this nomenclature in this topic review. The WHO classification system is described in detail elsewhere. (See "Overview of pulmonary hypertension in adults", section on 'Classification'.)


Endogenous nitric oxide (NO) has a normal role in healthy patients, which is interrupted in patients with PAH.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Aug 25, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. http://clinicaltrials.gov/show/NCT01457781 (Accessed on August 24, 2015).
  2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524.
  3. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173.
  4. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004; 109:3106.
  5. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149:538.
  6. Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994; 91:7583.
  7. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.
  8. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384.
  9. Pearl JM, Nelson DP, Raake JL, et al. Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med 2002; 30:89.
  10. Zapol WM, Rimar S, Gillis N, et al. Nitric oxide and the lung. Am J Respir Crit Care Med 1994; 149:1375.
  11. Nong Z, Hoylaerts M, Van Pelt N, et al. Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats. Circ Res 1997; 81:865.
  12. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993; 88:2884.
  13. Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol 2015; 31:407.
  14. Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998; 114:208S.
  15. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70.
  16. Fagan KA, Fouty BW, Tyler RC, et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 1999; 103:291.
  17. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96:442.
  18. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost 2003; 1:2112.
  19. Greenberg B, Rhoden K, Barnes PJ. Endothelium-dependent relaxation of human pulmonary arteries. Am J Physiol 1987; 252:H434.
  20. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214.
  21. Cremona G, Higenbottam T, Borland C, Mist B. Mixed expired nitric oxide in primary pulmonary hypertension in relation to lung diffusion capacity. QJM 1994; 87:547.
  22. Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:917.
  23. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:1061.
  24. Demoncheaux EA, Higenbottam TW, Kiely DG, et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005; 42:133.
  25. Granton J, Langleben D, Kutryk MB, et al. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circ Res 2015; 117:645.
  26. Jolliet P, Bulpa P, Thorens JB, et al. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997; 52:369.
  27. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32:1068.
  28. Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98:225.
  29. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125:580.
  30. Preston IR, Sagliani KD, Roberts KE, et al. Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ 2013; 3:68.
  31. Arunthari V, Heckman MG, Burger CD. Prevalence of acute vasoresponsiveness in patients with pulmonary hypertension: treatment implications. South Med J 2010; 103:630.
  32. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105.
  33. Malhotra R, Hess D, Lewis GD, et al. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ 2011; 1:250.
  34. Hill NS, Preston IR, Roberts KE. Inhaled Therapies for Pulmonary Hypertension. Respir Care 2015; 60:794.
  35. Snell GI, Salamonsen RF, Bergin P, et al. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1263.
  36. Koh E, Niimura J, Nakamura T, et al. Long-term inhalation of nitric oxide for a patient with primary pulmonary hypertension. Jpn Circ J 1998; 62:940.
  37. Channick RN, Newhart JW, Johnson FW, et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996; 109:1545.
  38. http://clinicaltrials.gov/show/NCT01457781 (Accessed on August 01, 2013).
  39. Jeffery M, Taichman DB. Management of the acutely ill patient with pulmonary arterial hypertension. In: Pulmonary Vascular Disease, Mandel J, Taichman DB (Eds), Elsevier Science, Philadelphia 2006. p.254.
  40. Mizutani T, Layon AJ. Clinical applications of nitric oxide. Chest 1996; 110:506.
  41. Bhorade S, Christenson J, O'connor M, et al. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999; 159:571.
  42. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127:1058.
  43. Meade MO, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167:1483.
  44. Cornfield DN, Milla CE, Haddad IY, et al. Safety of inhaled nitric oxide after lung transplantation. J Heart Lung Transplant 2003; 22:903.
  45. Takaba K, Aota M, Nonaka M, et al. Successful treatment of chronic thromboembolic pulmonary hypertension with inhaled nitric oxide after right ventricular thrombectomy. Jpn J Thorac Cardiovasc Surg 2004; 52:257.
  46. Fattouch K, Sbraga F, Sampognaro R, et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7:119.
  47. Rossaint R, Falke KJ, López F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399.
  48. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998; 56:989.
  49. Katayama Y, Higenbottam TW, Diaz de Atauri MJ, et al. Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 1997; 52:120.
  50. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001; 59:5.
  51. Narula P, Xu J, Kazzaz JA, et al. Synergistic cytotoxicity from nitric oxide and hyperoxia in cultured lung cells. Am J Physiol 1998; 274:L411.
  52. Christenson J, Lavoie A, O'Connor M, et al. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000; 161:1443.